{"id":31596,"date":"2022-10-19T11:43:33","date_gmt":"2022-10-19T09:43:33","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=31596"},"modified":"2022-10-25T08:17:35","modified_gmt":"2022-10-25T06:17:35","slug":"die-angepassten-vakzinen-gegen-sars-cov-2-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/die-angepassten-vakzinen-gegen-sars-cov-2-cme","title":{"rendered":"Die angepassten Vakzinen gegen SARS-CoV-2   [CME]"},"content":{"rendered":"<p>Seit Beginn der SARS-CoV-2-Pandemie tauchen neue Virus-Varianten auf, wie Beta (B.1.351), Delta (B.1.617.2) und Omikron (B.1.1.529 [BA.1]) mit seinen Untervarianten (BA.2, BA.2.12.1, BA.4, BA.5). Unter dem Selektionsdruck der zunehmenden Immunit\u00e4t in der Bev\u00f6lkerung wandelt sich das SARS-CoV-2 in Richtung einer h\u00f6heren Infektiosit\u00e4t und geringeren Pathogenit\u00e4t. Nach Einsch\u00e4tzung des Robert Koch-Instituts ist die Schutzwirkung der bisherigen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seit Beginn der SARS-CoV-2-Pandemie tauchen neue Virus-Varianten auf, wie Beta (B.1.351), Delta (B.1.617.2) und Omikron (B.1.1.529 [BA.1]) mit seinen Untervarianten (BA.2, BA.2.12.1, BA.4, BA.5). Unter dem Selektionsdruck der zunehmenden Immunit\u00e4t in der Bev\u00f6lkerung wandelt sich das SARS-CoV-2 in Richtung einer h\u00f6heren Infektiosit\u00e4t und geringeren Pathogenit\u00e4t. Nach Einsch\u00e4tzung des Robert Koch-Instituts ist die Schutzwirkung der bisherigen [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5744,5745,5340,5339,1107,1455,5338,5522,5746],"class_list":["post-31596","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-comirnaty-original-omicron-ba-1","tag-comirnaty-original-omicron-ba-4-5","tag-coronavirus","tag-covid-19","tag-impfstoffe","tag-impfung","tag-sars-cov-2","tag-schutzimpfung","tag-spikevax-bivalent-original-omicron-ba-1"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/31596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=31596"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/31596\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=31596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=31596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=31596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}